Farmacia Nordic Ab

What Farmacia Nordic Ab does

Farmacia Nordic AB is a privately-held Swedish pharmaceutical and medical technology company headquartered in Askim, Sweden, founded in 2024. The company develops and distributes over-the-counter (OTC) medical devices in two therapeutic categories: ear care and gastrointestinal health. Its core product portfolio consists of three SKUs — Vaxol® ear spray (a pharmaceutical-grade olive oil and mineral oil formulation that softens earwax and lubricates dry ear canals), Vaxol® Baby (a pediatric variant approved for children from 6 months of age), and Silicolgel (a silicic acid-based medical device for treatment of heartburn, acid reflux, bloating, nausea, and IBS symptoms). A fourth product, Recigar, is also referenced on the company website.

The company's commercial foundation rests on its March 2024 acquisition of Vaxol Ltd, which transferred global trademark and distribution rights to the Vaxol brand — a product established in over 20 European markets with market-leading positions in several countries. Vaxol is notably the first oil-based ear product approved under the European Medical Device Regulation (MDR), providing a regulatory differentiator.

Farmacia Nordic operates a hybrid distribution model: it maintains an in-house sales and marketing function for the Nordic region while distributing across the rest of Europe through a network of third-party distributors. The company is actively seeking additional distribution partners globally and is positioned as being in its startup phase. End customers are individual consumers purchasing OTC products through pharmacies and retail channels; pricing details are not publicly disclosed, and revenue figures have not been released. Johan Bloom serves as CEO.

Name

Farmacia Nordic Ab

Legal name

Farmacia Nordic AB

Website

https://farmacianordic.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

Farmacia Nordic AB is a privately-held Swedish pharmaceutical and medical technology company that develops and distributes OTC ear care (Vaxol, Vaxol Baby) and gastrointestinal (Silicolgel, Recigar) medical devices across 20+ European markets via distributor networks and direct Nordic sales.

Ownership category

akta.pro rank

Product category

OTC Pharmaceuticals

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Digestive Health OTC (Antacids, Laxatives, Anti-diarrheals, Probiotics OTC) (CRADAMAE)

akta.pro secondary industry

Pediatric OTC Medicines (HLAIADAL)

Keywords

• Otc pharmaceuticals
• Medical devices
• Ear care products
• Digestive health products
• Consumer healthcare

Headquarters

HQ city

Askim

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Marketing or Sales, Operations, Supply Chain, Technology or R&D

Revenue model

1. Product Sales: Sale of OTC pharmaceutical and medical technology products including ear care sprays (Vaxol, Vaxol Baby) and digestive health products (Silicolgel). Products are sold through distribution networks across Europe.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Farmacia Nordic AB is a privately-owned Swedish pharmaceutical and medical technology company that develops and distributes over-the-counter (OTC) prescription-free medical device products. Its portfolio centers on the Vaxol ear care spray line (Vaxol and Vaxol Baby) for earwax removal and ear canal lubrication, and Silicolgel, a silicic acid-based product for acute and chronic digestive problems. Products are sold through a network of distributors and European retail pharmacies across more than 20 countries.

Product overview

Farmacia Nordic AB is a privately-owned Swedish pharmaceutical and medical technology company operating primarily in the Nordic region with a broad European network. The company offers three core products: Vaxol® ear spray (a pharmaceutical-grade olive oil and mineral oil formulation for earwax removal and ear canal care), Vaxol® Baby (a pediatric variant approved for children from 6 months), and Silicolgel (a silicic acid-based product for digestive health treating conditions like heartburn, reflux, and IBS). The company acquired Vaxol Ltd in March 2024 to take over global rights and distribution of the Vaxol brand, establishing itself as a leading player in ear care across over 20 markets.

Differentiator

Problem solved

Functional benefit

Brands

• Vaxol®: Prescription-free ear spray that softens wax plugs and lubricates dry ear canals. Based on pharmaceutical-grade olive oil with purified mineral oil. MDR approved ear care product sold in 20+ European countries.
• Vaxol® Baby
• Silicolgel

Products and services

• Vaxol Ear Spray Prescription-free ear spray for the ear canal that softens and removes earwax and wax plugs. Lubricates and moisturizes the skin, relieves itching and irritation, and protects the ear from water. Made mainly of pharmaceutical-grade olive oil and a small amount of mineral oil. The first oil-based ear product approved under the Medical Device Regulation (MDR). Sold OTC in pharmacies across Europe.
• Vaxol Baby Ear spray specifically approved for children from 6 months of age for wax removal and ear cleaning. Creates a protective barrier in the ear canal, shielding it from dirt and water while preserving natural moisture. Designed for children's smaller, narrower ear canals which are more sensitive and prone to wax buildup.
• Silicolgel

Quantifiable outcome

• Products available in over 20 countries across Europe
• +1 more outcomes

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Distributors (Seeking)coreChannel Partner/ Reseller/ DistributorFarmacia Nordic is continuously seeking business partners and distributors for future interesting projects. The company is looking to expand its global network of distributors and welcomes potential collaboration partners to contact them.
• Vaxol LtdcoreOEM/ Whitelabel/ Licensing PartnerFarmacia Nordic AB acquired Vaxol Ltd on March 26, 2024, taking over the trademark rights and distribution of Vaxol products globally. Vaxol Ltd was the original owner of the prominent Vaxol ear care brand.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Reckitt Benckiser: Reckitt owns Gaviscon and operates one of the world's largest consumer health OTC portfolios, providing a broad-based incumbent counterweight across digestive and consumer health categories.
• Church & Dwight: Church & Dwight is the owner of the Otex ear care brand and a major diversified OTC consumer health company, representing a scaled incumbent competing across the same ear care and OTC categories.

Direct peers

• Earol: Earol is an olive-oil based ear spray for wax softening and ear canal lubrication; it is the closest direct competitor to Vaxol in terms of formulation, route of administration, and OTC positioning.
• Otex (Church & Dwight): Otex is an OTC ear wax removal drops range sold across UK and European pharmacies, competing head-to-head with Vaxol for ear wax self-treatment shelf space.
• Silicol: Silicol markets a silicic acid gel for digestive complaints (reflux, IBS), the original category-creator product against which Farmacia Nordic's Silicolgel is directly positioned.
• Imodium (Johnson & Johnson / Kenvue): Imodium is a leading OTC anti-diarrheal brand, addressing a digestive symptom set that overlaps with Silicolgel's claimed indications (diarrhea, stomach pain).
• Earex: Earex is an OTC ear care product range addressing ear wax and ear discomfort, competing directly with Vaxol in pharmacy and retail OTC channels.
• Rennie (Bayer): Rennie is Bayer's leading OTC antacid brand used for heartburn and indigestion, competing for the same digestive self-care shelf space as Silicolgel.
• Cerumol: Cerumol is an established OTC ear wax removal product (drops) used across European pharmacy channels, serving the same consumer use cases as Vaxol.
• Gaviscon (Reckitt Benckiser): Gaviscon is a flagship OTC heartburn and reflux brand from Reckitt; it competes for the same consumer digestive-health self-treatment occasions as Silicolgel.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/farmacia-nordic

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Farmacia Nordic Ab